@article{f4b9091701634f59a2d07219a97a706a,
title = "Trust your gut when it comes to driving CARs",
abstract = "Chimeric Antigen Receptor (CAR) T-cells have revolutionized the treatment of hematologic malignancies, but limitations exist in poor predictability and in observable toxicity with response to treatment. Here, Smith et al. present the gut microbiome as an actionable (and potentially targetable) biomarker of response and toxicity with (CD19) CAR T-cell treatment.1",
author = "Manoj Chelvanambi and Wargo, {Jennifer A.}",
note = "Funding Information: J.A.W. is an inventor on a US patent application (PCT/US17/53.717); reports compensation for speaker's bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, MedImmune, and Bristol-Myers Squibb (BMS); serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline (GSK), BMS, Merck, Biothera Pharmaceuticals, and Micronoma. J.A.W. holds stock options from Micronoma. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = may,
day = "13",
doi = "10.1016/j.medj.2022.04.015",
language = "English (US)",
volume = "3",
pages = "281--283",
journal = "Med",
issn = "2666-6359",
publisher = "Cell Press",
number = "5",
}